{"id":"W2148643283","doi":"10.1056/nejmoa1207506","title":"Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy","year":2012,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4574,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency; Université de Montréal","funders":"Janssen Pharmaceuticals; Chugai Pharmaceutical; Genentech; Cilag; Astellas Pharma; Teva Pharmaceutical Industries; Eisai; Sanofi; Memorial Sloan-Kettering Cancer Center; GlaxoSmithKline; Amgen; Pfizer; Active Biotech; Celgene; Astellas Pharma Global Development; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Enzalutamide; Prostate cancer; Medicine; Androgen receptor; Oncology; Overall survival; Internal medicine; Chemotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009962156,0.0002860651,0.0008682465,0.0002546379,0.0001180667,0.0002356401,0.0002016901,0.000336168,0.001133234],"category_scores_gemma":[0.001156323,0.0001094928,0.0006519877,0.000334395,0.0003284787,0.0002066511,0.0001521511,0.000631663,0.0000652963],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003153665,"about_ca_system_score_gemma":0.0003450346,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004014628,"about_ca_topic_score_gemma":0.0008590705,"domain_scores_codex":[0.9996808,0.0001875939,0.00002254976,0.00004076717,0.00003322373,0.00003509664],"domain_scores_gemma":[0.9992049,0.0003810645,0.0002452313,0.00003259386,0.00003224733,0.000103912],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.5460542,0.006666798,0.07803685,0.002799702,0.002889545,0.0003792924,0.00020536,0.004534184,0.04777497,0.0003090865,0.001424397,0.3089256],"study_design_scores_gemma":[0.153027,0.4595539,0.358328,0.0004117094,0.004856314,0.001473385,0.00008165435,0.00297529,0.01193344,0.0007116934,0.006590385,0.00005727688],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9877994,0.01097316,0.0002541485,0.0001324553,0.00004936554,0.0001158955,0.0000974295,0.00002074815,0.0005573311],"genre_scores_gemma":[0.9967045,0.002531873,0.0002403734,0.0001274907,0.0000596415,0.00005078738,0.0001245713,0.000003234269,0.0001576],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001133234,"threshold_uncertainty_score":0.005268574,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0203892061612365,"score_gpt":0.3202014771681385,"score_spread":0.299812271006902,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}